Benign Prostatic Hyperplasia
Over 12 weeks of treatment, the mean number of nocturia episodes decreased by 1.1 and 0.9 in men who were and were not bothered by their symptoms, a non-significant difference between groups.
Men with metabolic syndrome or a smoking history had more than triple the risks for persistent moderate to severe nocturia after TURP.
Clinicians tend to focus on the number of voids, but patients worry more about interrupted sleep.
The procedure improves symptoms at least as well in men with obstructive middle lobes as those with obstructive lateral lobes.
Men older than 50 with metabolic syndrome had significantly greater risks for BPH than men without the syndrome.
New clinical guidelines for the surgical management of lower urinary tract symptoms attributable to enlarged prostate offer 22 recommendations.
Dementia link seen with antidepressant, urological, and anti-Parkinson's drugs.
A previous study showed that using 5-ARIs to treat benign prostate hyperplasia decreased the risk of low-grade PCa.
Men using allopurinol had a 22% lower risk of a BPH diagnosis.
Decrease in scores on the Men's Sexual Health Questionnaire mostly due to ejaculation disorders.
A novel approach called "Aquablation" provides results comparable to TURP, but with a decreased likelihood of retrograde ejaculation.
Patients who underwent the minimally invasive procedure had a 36%, 50%, and 44% improvement in IPSS, quality of life, and peak flow rate, respectively, at 5 years.
Long-term use of the drug may predispose men to worsening erectile dysfunction and elevated risk of diabetes and non-alcoholic fatty liver disease.
PUL involves placement of small permanent metallic implants into the prostate that lift the lateral lobes away from the urethra and remove obstruction.
NSAID users had a 2-fold increased risk of BPH medication use, 59% increased risk of a recorded BPH diagnosis, and 61% increased risk for BPH surgery.
Average International Prostate Symptom Score remained low 5 years after the PVP laser procedure.
Researchers identified a predictor of new-onset UI after HoLEP that may aid urologists in clinical practice.
In a study, 81.1% of men were able to void after an average of 28 days after treatment.
In a study, 86% of prostatic urethral lift patients experienced symptom relief in the first month.
Study confirms small, but significant increases in the risks of these mental health problems among men taking the medication.
The finasteride and dutasteride recipients had significantly less mean blood loss than the placebo group.
Benign prostatic hyperplasia is more likely to develop among men with larger waist circumference and body mass index and higher leptin levels.
Poor baseline functional status and having a Foley catheter preoperatively were associated with greater risk of TURP or TULIP failure.
New findings confirm previous reports.
The procedure may be particularly efficacious for men with very large prostates.
Use of 5ARIs for BPH was associated with a statistically significant increased, pooled relative risk for sexual dysfunction.
In a meta-analysis, men with benign prostatic hyperplasia had a 2.9 times and 1.7 times increased incidence of prostate cancer and bladder cancer, respectively.
Patients experienced a sustained decrease in AUA Symptom Score, and 95% of patients report being satisfied or very satisfied with the procedure.
Renal and Urology News Articles
- Aggressive Therapy Warranted for Gleason 10 Prostate Cancer
- PET/CT May Improve Imaging of Recurrent Prostate Cancer
- Adding MRI Does Not Boost Prostate Cancer Upgrading Rate
- Both High and Low Uric Acid Levels Tied to Higher Mortality
- Trulicity Labeling Updated to Include Data on T2D Patients With CKD
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)